FATE Q3 2020 Earnings — Fate Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

FATEFate Therapeutics, Inc.

$142M

Q3 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$8M+211.2% YoY

Gross Profit

-$23M-306.1% margin

Operating Income

-$31M-416.6% margin

Net Income

-$59M-776.4% margin

EPS (Diluted)

$-0.68

QoQ Revenue Growth

+38.3%

Cash Flow

Operating Cash Flow

-$31M

Free Cash Flow

-$32M

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$626M

Total Liabilities

$202M

Stockholders' Equity

$424M

Cash & Equivalents

$349M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$8M	$2M	+211.2%
Gross Profit	-$23M	-$21M	-11.4%
Operating Income	-$31M	-$27M	-16.1%
Net Income	-$59M	-$27M	-120.5%